一品红(300723.SZ)：全资子公司获得注射用硫酸艾沙康唑注册证书

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for the injection of Sulfate Isavuconazole, indicating a significant advancement in its product portfolio and potential market impact [1] Company Summary - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted a drug registration certificate for injectable Sulfate Isavuconazole [1] - The approved injectable Sulfate Isavuconazole is classified as a Category 4 chemical drug and has passed the consistency evaluation [1] Product Details - Injectable Sulfate Isavuconazole is indicated for the treatment of adult patients with invasive fungal infections, specifically invasive aspergillosis and invasive mucormycosis [1] - The product is categorized as a Class B product under the national medical insurance scheme [1] Market Potential - According to data from Minet, the sales scale of injectable Sulfate Isavuconazole in urban and county-level public hospitals in China is projected to be approximately 225.05 million RMB in 2024 [1]